Opdivo Set To Be First PD-1 Inhibitor In EU After CHMP’s April Drug Reviews
This article was originally published in The Pink Sheet Daily
Executive Summary
Europe’s Committee for Medicinal Products for Human Use recommended Bristol-Myers Squibb’s PD-1 inhibitor Opdivo for marketing approval for melanoma and also recommended Vanda’s sleep disorder therapy Hetlioz and Daiichi Sankyo’s once-daily oral anticoagulant Lixiana.